麻豆传媒

Personalized recs were made by team of physicians and pharmacists within an hour of diagnosis

Trial follow-up defines the need for long-term treatment in protecting the kidneys and heart

Observational study points to genetic risk allele dose-response

Anti-mineralocorticoid agent reduced albuminuria, but not eGFR-based kidney outcome

Ravulizumab reduced proteinuria, stabilized eGFR in IgA nephropathy

Surrogate endpoint of urinary protein-to-creatinine ratio "widely considered to be predictive"

Treatment with iptacopan reduces proteinuria in interim APPLAUSE-IgAN analysis

Study also raises question of antibiotic prophylaxis in kids with common congenital anomaly

Study details an intermediate prognosis with newer microvascular inflammation phenotypes

Plus: bardoxolone methyl for diabetic kidney disease and spironolactone in hemodialysis patients

Trial tested BI 690517 with and without empagliflozin

Multi-pronged approach to boost living and deceased donor transplant fails in randomized trial

Proteinuria reduction and slower eGFR decline in 2-year PROTECT trial

But ZENITH-CKD trial had to pivot to only using low-dose zibotentan due to fluid retention